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Small ubiquitin-related modifier (SUMO) proteins are conjugated to numerous polypeptides in cells, and
attachment of SUMO plays important roles in regulating the activity, stability, and subcellular localization of
modified proteins. SUMO modification of proteins is a dynamic and reversible process. A family of SUMO-
specific proteases catalyzes the deconjugation of SUMO-modified proteins. Members of the Sentrin (also
known as SUMO)-specific protease (SENP) family have been characterized with unique subcellular localiza-
tions. However, little is known about the functional significance of or the regulatory mechanism derived from
the specific localizations of the SENPs. Here we identify a bipartite nuclear localization signal (NLS) and a
CRM1-dependent nuclear export signal (NES) in the SUMO protease SENP2. Both the NLS and the NES are
located in the nonhomologous domains of SENP2 and are not conserved among other members of the SENP
family. Using a series of SENP2 mutants and a heterokaryon assay, we demonstrate that SENP2 shuttles
between the nucleus and the cytoplasm and that the shuttling is blocked by mutations in the NES or by treating
cells with leptomycin B. We show that SENP2 can be polyubiquitinated in vivo and degraded through
proteolysis. Restricting SENP2 in the nucleus by mutations in the NES impairs its polyubiquitination, whereas
a cytoplasm-localized SENP2 made by introducing mutations in the NLS can be efficiently polyubiquitinated,
suggesting that SENP2 is ubiquitinated in the cytoplasm. Finally, treating cells with MG132 leads to accu-
mulation of polyubiquitinated SENP2, indicating that SENP2 is degraded through the 26S proteolysis pathway.
Thus, the function of SENP2 is regulated by both nucleocytoplasmic shuttling and polyubiquitin-mediated
degradation.
Reversible posttranslational modification plays an important
role in regulating functions of the modified proteins by altering
their activity, stability, and localization, as well as their inter-
action with other molecules. Some modifications consist of
small chemical groups, such as phosphate, acetate, lipids, and
sugar, that are added to specific amino acids. Another type of
modification is the covalent attachment of other polypeptides
to the target proteins. The most well known example of such
polypeptide modifiers is ubiquitin (Ub), a modifier playing a
major role in targeting proteins for proteolytic degradation
(13). The group of small ubiquitin-related modifiers (SUMO),
like ubiquitin, covalently modify a large number of proteins
and play important roles in many cellular processes, including
the regulation of gene expression, histone modification, DNA
repair, and nucleocytoplasmic shuttling (18). Three members
of the SUMO family in vertebrates have been described:
SUMO-1 and its close homologs SUMO-2 and SUMO-3. All
three can be linked to substrate proteins through a process
called sumoylation. The mechanism of sumoylation is very
similar to that of ubiquitination, which requires sequential
actions of an E1-activating enzyme, an E2-conjugating enzyme,
and an E3-ligating enzyme (9, 22). Recently, a fourth member
of SUMO (SUMO-4) was discovered, and its expression ap-
pears to be restricted to the kidneys (5, 11).
Sumoylation is a dynamic and reversible process. Sentrin
(also known as SUMO)-specific proteases (SENPs) participate
in both the processing of immature SUMO proteins and the
removal of SUMO conjugates from SUMO-modified sub-
strates (23). The first SUMO-specific protease identified was
Ulp1, a yeast protein found to be essential for the G2/M cell
cycle transition (17). To date, at least seven mammalian or-
thologs of Ulp1 have been identified (23), and at least four of
them have been confirmed to have SUMO protease activity
(19). The proteases identified so far possess several interesting
features. All contain the conserved catalytic triad in the C-
terminal domain consisting of several highly conserved amino
acids (cysteine, histidine, and aspartic acid). They possess a
large N-terminal domain with minimal or no homology to each
other’s domain. It has been suggested that the diversified N-
terminal domains of SENP proteases determine their substrate
specificity by controlling their subcellular localization (2, 12,
24). Mammalian SENPs are found in many different subcellu-
lar compartments: the nucleoplasm, nucleolus, nuclear enve-
lope, nuclear bodies, and cytoplasm. It has been shown that
SENP1 localizes to the nucleoplasm (10), SENP2 localizes to
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the nuclear side of the nuclear pore complex (NPC) (24),
SENP3 localizes to the nucleolus (20), and SENP6 localizes
predominantly to the cytoplasm (16). Although very little is
known about the substrate specificity of each of the SENP
enzymes, their distinct subcellular localizations have been pos-
tulated to play important roles in their function, particularly in
substrate selection (19, 23). Nevertheless, how the unique sub-
cellular localization of each SENP is regulated remains un-
known.
It has been shown that the N-terminal 63 amino acid resi-
dues are required for SENP2 to localize to the NPC (24),
indicating that they may contain the nuclear localization signal
(NLS) sequence. The same N-terminal area in SENP1, how-
ever, is not essential for its nuclear import. Instead, the NLS of
SENP1 is found at amino acid residues 171 to 177 (2). The
different locations of the NLS in SENP1 and SENP2 under-
score the role of the N-terminal domains of SENP enzymes in
their diversified cellular functions. Here, we report the identi-
fication of a bipartite NLS sequence in the N-terminal domain
and a leucine-rich, CRM1-dependent nuclear export signal
(NES) sequence in the central domain of SENP2. Consistent
with a protein containing both an NLS and an NES, our data
FIG. 1. A sequence alignment of human SENP1 (hSENP1) and SENP2 potentially reveals NLS and NES in SENP2 in unconserved domains.
(A) Amino acid sequence alignment of human SENP1 and SENP2 using the CLUSTAL W (version 1.81) multiple-sequence alignment program.
The fully conserved residues and the conservation of strong groups are indicated by a black background and a light-gray background, respectively.
The NLS and the NES sequences of SENP2 are indicated with underlines. The NLS of SENP1 is indicated with a box. Key amino acid residues
involved in the catalytically active site are marked as asterisks. The conserved domain of SENP family proteins is shown with dotted lines above
the sequence. (B) Diagram of human SENP2 with positions and amino acid sequences of the two predicted bipartite NLSs. The functionally
important basic amino acids of each NLS are shown in boldface. Alanine substitutions to generate SENP2 NLS mutants are indicated. cNLS,
C-terminally located putative NLS.
FIG. 2. Identification of a bipartite NLS in SENP2. (A) Localization of wild-type SENP2 and SENP2 NLS mutants. U2OS cells were
transfected with the indicated Myc-tagged SENP2 plasmids. Twenty-four hours after transfection, cells were fixed and immunostained with an
anti-Myc antibody (-Myc; 9E10.3), followed by staining with Cy2-conjugated secondary antibody. Immunofluorescent, phase-contrast, and
DAPI-stained images are shown. (B) Quantification of SENP2 mutants in nuclear and cytoplasmic fractions. Low-magnification pictures of
immunostained SENP2 are shown. The graphs show the percentage of cells in each subcellular fraction as determined by counting at least 200 cells
in each sample.
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demonstrate that SENP2 shuttles between the nucleus and the
cytoplasm. Intriguingly, we found that SENP2 can be poly-
ubiquitinated in vivo and that the polyubiquitination can be
impaired by restricting the protein’s localization to the nucleus.
Together, our data indicate that nucleocytoplasmic shuttling is
a crucial regulatory mechanism for SENP2 function.
MATERIALS AND METHODS
Plasmids. The constructs of Flag-tagged SENP2, His-tagged PML and Ran-
GAP1, and hemagglutinin (HA)-tagged SUMO-1 and SUMO-3 were described
previously (7). A catalytically inactive SENP2 mutant (SENP2Cat) (R576L,
K577M) was prepared by standard cloning and PCR-based mutagenesis. SENP2
cDNA from Flag-tagged constructs was subcloned into pcDNA3 (Invitrogen),
which was engineered to contain an in-frame amino-terminal Myc tag to gener-
ate Myc-tagged SENP2. SENP2 enzymes with mutations in the NLS and NES
(SENP2mNLS and SENP2mNES, respectively) were prepared by standard cloning
and PCR-based mutagenesis and verified by DNAsequencing. The oligonucleo-
tides for generating the NES-yellow fluorescent protein (YFP) fusions were










AGCCATCTGTACATG for the SENP2(1–15) mutant, and CTAGCATGCTGG
AGCCTGACCTATCAGAAGAAGTGTCGGCCCGAGCTCGCGCCGGC
GTAC and GCCGGCGCGAGCTCGGGCCGACACTTCTTCTGATAGGTCA
GGCTCCAGCATG for the SENP2(317–332) mutant]. The oligonucleotide pairs
were denatured at 95°C for 3 min, annealed by slowly cooling them to room tem-
perature for 30 min, and inserted into the NheI and KpnI sites of the N terminus of
the YFP vector to generate in-frame YFP fusion proteins as described previously
(21). SENP2 wild-type and SENP2mNES mutant cDNAs from Myc-tagged constructs
were subcloned into the pcDNA-EGFP-C4 vector (Invitrogen) to construct green
fluorescent protein (GFP) fusion proteins. The cDNA fragments of SENP2 deletion
mutants were amplified by PCR using the following primers: AAAAAGATCTGT
GCTGCCAGCTTATTTGGATTCCCAT (used as a forward primer for all deletion
mutants), CCCGTCTAGATCATAGGGCATTACTGATTTCCTTTTCCATG
[used as a reverse primer for the SENP2(66–380) mutant], CCCGTCTAGATCAA
GTAATTCGCAATTTGAAAGCACTACTTAGGATT [used as a reverse primer
for the SENP2(66–398) mutant], and GCCCTCTAGATCACAGCAACTGCTGA
TGAAGGATTTC [used as a reverse primer for the SENP2(66–589) mutant].
pcDNA3-Myc-SENP2 wild-type or SENP2mNES mutant plasmids were used for
templates and PCR products cloned into the pcDNA3-EGFP-C4 vector. The GFP
plasmid construct loading control for transfection efficiency was purchased from BD
Bioscience Clontech (pEGFP-N1; catalog no. 6085-1). HA-tagged Ub (HA-Ub) is a
gift from Yue Xiong (The University of North Carolina, Chapel Hill, NC).
Cell lines and cell culture. The human osteosarcoma U2OS cell line and
human lung tumor H1299 cell line were purchased from the ATCC. Mouse
embryonic fibroblast (MEF) cells were isolated in the lab. All cells were routinely
maintained in a 37°C incubator with 5% CO2 in Dulbecco’s modified Eagle’s
medium with 10% fetal bovine serum. In all cases, cells were transfected using
Effectene transfection reagent (QIAGEN) or Fugene6 (Roche) according to the
manufacturer’s instructions.
In vivo sumoylation assay. Cells were lysed in 2% sodium dodecyl sulfate
(SDS) lysis buffer (2% [wt/vol] SDS, 50 mM Tris-HCl [pH 6.8], 10% glycerol).
Two percent SDS lysis buffer was preheated to 95°C before being added to the
cells to protect SUMO-conjugated proteins from desumoylation during protein
preparation. Proteins were separated by SDS-polyacrylamide gel electrophoresis
(PAGE) and transferred to nitrocellulose membranes. The blots were blocked in
5% nonfat dried milk in PBST (phosphate-buffered saline [PBS] containing 0.1%
[vol/vol] Tween 20) and incubated with primary antibodies and horseradish
peroxidase-labeled secondary antibodies in the blocking buffer. The blots were
thoroughly rinsed with PBST after each incubation. Antibodies were detected
with chemiluminescence detection reagents according to the manufacturer’s
instructions (Pierce). Flag (M2; Sigma), Myc (9E10.3; NeoMarkers), HA (16B12;
COVANCE), His (RGS-His; QIAGEN), actin (Chemicon), Ku80 (NeoMarkers),
and GFP (Research Diagnostics) antibodies were purchased. Rabbit anti-Myc
antibody was a gift from Yue Xiong (University of North Carolina, Chapel Hill,
NC). GFP was used as a loading control for transfection efficiency.
In vivo ubiquitination assay. H1299 cells were transiently transfected with
Myc-tagged SENP2 along with HA-tagged ubiquitin plasmid DNA. GFP plasmid
was cotransfected as a control for transfection efficiency. Two days after trans-
fection, cells were treated with 20 M MG132 for 6 h and then lysed in 1% SDS
lysis buffer (1% [wt/vol] SDS and 1% [wt/vol] NP-40 in PBS). The cell lysates
were diluted 10 times with 0.1% NP-40–PBS containing 1 mM phenylmethylsul-
fonyl fluoride (PMSF). The diluted lysates were precleaned with Sepharose
CL4B beads (Sigma) for 30 min and then immunoprecipitated with rabbit anti-
Myc antibody overnight at 4°C, followed by incubation with protein A/G beads
(Pierce) for 2 h at 4°C. The beads were washed four times with cold 0.1%
NP-40–PBS containing 1 mM PMSF. The beads were then incubated in 1 SDS
loading buffer (100 mM Tris-HCl [pH 6.8], 2% [wt/vol] SDS, 0.2% bromophenol
blue, 10% glycerol, 100 mM dithiothreitol) at 100°C for 2 min, followed by
SDS-PAGE. After electrophoresis, the proteins were transferred to nitrocellu-
lose membranes. The membranes were blocked in 5% nonfat dry milk in PBST
and incubated with primary antibodies and horseradish peroxidase-labeled second-
ary antibodies in the blocking buffer. Antibodies were detected with chemilumines-
cence detection reagents according to the manufacturer’s instructions (Pierce).
Protein half-life assay. H1299 cells were transfected with Myc-tagged SENP2
constructs. Twenty-four hours after transfection, cells were pulsed with [35S]me-
thionine for 2 h and then chased for the lengths of time indicated in Fig. 8A and
B. Cells were collected and lysed in 0.5% NP-40 lysis buffer (50 mM Tris-HCl
[pH 7.5], 150 mM NaCl, 0.5% [wt/vol] NP-40, 50 mM NaF, 1 mM NaVO3, 1 mM
dithiothreitol, 1 mM PMSF, protease inhibitors). The cell lysates were immuno-
precipitated with mouse anti-Myc antibody (9E10) overnight and with protein
A/G for 1 h at 4°C. The beads were washed three times with 0.5% NP-40 lysis
buffer. The resulting SENP2 immunoprecipitates were separated by SDS-PAGE
and visualized by autoradiography. The amount of labeled SENP2 protein at
each time point was quantified on a PhosphorImager and normalized relative to
the amount of radiolabeled SENP2 present in cells following the 0 h chase.
Indirect immunofluorescence. Cultured cells were seeded in six-well plates
and transfected with plasmid DNA. Twenty-four hours after transfection, cells
were washed three times with PBS and fixed in PBS containing 4% formaldehyde
for 10 min. After fixation, cells were washed twice with PBS, permeabilized in
cold PBS containing 0.2% Triton X-100 for 5 min, and incubated with blocking
buffer (PBS containing 0.5% bovine serum albumin) for 30 min prior to incu-
bation with the primary antibody in the blocking buffer for 1 h. The cells were
then incubated with Cy2-conjugated or rhodamine-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories) for 30 min. Cells were washed
three times with PBS and finally counterstained with DAPI (4,6-diamidino-2-
phenylindole). Stained cells were covered by antifluorescent mounting medium
(DAKO) and examined with an Olympus model IX81 microscope fitted with
appropriate fluorescence filters.
FIG. 3. Identification of a CRM1-dependent NES in SENP2. (A) The consensus sequence for the CRM1-dependent nuclear export signal is
shown; the conserved hydrophobic amino acid can be leucine (L), isoleucine (I), methionine (M), or phenylalanine (F). (B) Diagram of SENP2
with the positions and amino acid sequences of three NES-like sites indicated. Alanine substitutions for NES functional essential hydrophobic
residues tested in the study are indicated. Superscript “m” indicates a mutant protein. (C) The SENP2 NES is a CRM1-dependent NES. Short
peptides of the putative SENP2 NES were fused with a YFP vector, and localization of the fusion proteins was observed in transfected U2OS cells.
Transfected cells were also treated with 10 nM LMB for 7 h to determine possible CRM1 dependency. Pictures were taken with living cells 24 h
after transfection. Corresponding phase-contrast pictures are shown. (D) Quantification of cells. Low-magnification pictures of transfected cells
are shown. The graph shows the percentages of cells with nuclear exclusion as determined by counting at least 200 cells.
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Heterokaryon assay. Heterokaryon assays were carried out essentially as de-
scribed previously (25). Human U2OS cells were transfected with plasmid DNA
expressing the GFP-SENP2 fusion proteins. After 12 h of incubation with the
plasmid, cells were washed twice with prewarmed PBS to remove untransfected
DNA. The cells were then trypsinized, mixed with wild-type MEF cells at a 1:1
ratio, and seeded onto a new dish. After another 12 h of incubation, the cells
were rinsed once with PBS and covered with a solution of 50% (wt/vol) PEG
8000 (Sigma-Aldrich) for 2 min at 37°C to induce cell fusion. After being washed
three times with PBS to remove the PEG, fused cells were continuously cultured
in Dulbecco’s modified Eagle’s medium–10% fetal bovine serum medium for 5 h.
Cycloheximide (50 g/ml; Sigma-Aldrich) was added to the culture 15 min
before and immediately after cell fusion to block de novo protein synthesis.
Subsequent cell fixation, permeabilization, and immunostaining followed stan-
dard immunofluorescence procedures. The cells were stained with a mouse
antibody recognizing human but not murine Ku nuclear antigen to distinguish
human and murine nuclei. Ku80 antibody was purchased from NeoMarkers.
RESULTS
Identification of a bipartite NLS in the N terminus of
SENP2. It has been shown recently that SENP1 has an NLS
(KKTQRR; see the boxed area in Fig. 1A) that is required for
SENP1 to enter the nucleus (2). However, sequence alignment
indicates that the SENP1 NLS is not conserved in other SENP
proteins, including SENP2 (Fig. 1A and data not shown). It has
been previously shown that SENP2 localizes to the inner nu-
clear membrane side of the NPC and that the N-terminal 63
amino acid residues of SENP2 are required for its nuclear
localization (24), indicating that an NLS may exist within this
sequence. Inspection of this area identified a stretch of amino
acids (KRRR) at residues 28 to 31 that resembles a basic
amino acid-rich NLS (Fig. 1B). To determine whether this
is the NLS of SENP2, we constructed a SENP2 mutant where
the middle two Arg residues were replaced with Ala
(KRRR3KAAR; SENP2mNLS1) and tested the localization of
the mutant by transient transfection and immunofluorescence
staining of U2OS cells. As shown in Fig. 2A, while there was no
cytoplasmic staining in the wild-type-SENP2-transfected cells
(row 1), cytoplasmic staining was clearly seen in the
SENP2mNLS1-transfected cells (row 2), indicating that the
KRRR sequence contributes to SENP2 nuclear localization.
However, the localization of the SENP2mNLS1 mutant was still
predominantly nuclear, indicating that even though the KRRR
sequence constitutes an NLS, the mutations only partially af-
fected its function. Further inspection of the SENP2 N-termi-
nal sequence revealed a pair of basic amino acids (KR) (Fig.
1B) 16 residues downstream of the KRRR sequence that,
when combined with the KRRR residues (KRRR-X16-KR),
would fit the consensus of a classic bipartite NLS (6). To
determine whether the KRRR-X16-KR sequence constitutes
a bipartite NLS, we generated two SENP2 mutants;
SENP2mNLS2 contains a KR3AA mutation, and SENP2mNLS
combines the KRRR3KAAR and KR3AA mutations (Fig.
1B). We then examined their localization in transiently trans-
fected U2OS cells by immunofluorescence staining. The
SENP2mNLS2 (KR3AA) mutant exhibited considerable cyto-
plasmic localization (Fig. 2A, row 3), indicating that the mu-
tations significantly affected the function of NLS. When both
parts of the putative NLS were mutated (KRRR3KAAR and
KR3AA), the mutant (SENP2mNLS) was exclusively localized
in the cytoplasm (Fig. 2A, row 4). Hence, we conclude that the
KRRR-X16-KR sequence constitutes a bipartite NLS in
SENP2. A quantitative summary of the mutational analysis is
shown in Fig. 2B. The data presented here are representative
of analysis of at least 200 positively transfected cells from
six independent experiments. Notably, the SENP2mNLS2 mu-
tant exhibited stronger cytoplasmic staining than did the
SENP2mNLS1 mutant, suggesting that the two parts of the bi-
partite NLS do not contribute equally to the nuclear import
activity of SENP2. Alternatively, the two remaining basic
amino acids in the SENP2mNLS1 mutant (KAAR) might retain
some nuclear import activity. We further tested another NLS-
like sequence at residues 475 to 489 of SENP2 that also fits the
consensus of a bipartite NLS (Fig. 1B) for its potential nuclear
import activity. Mutational analysis indicated that this C-ter-
minally located sequence is not a functional NLS. Instead, for
reasons yet unknown, the SENP2 mutant (SENP2mcNLS, where
the “c” indicates the C-terminal region) showed diminished
speckle formation, and the mutant SENP2 was rather toxic to
cells as judged by deformed nuclei and increased cell death
(Fig. 2A, rows 5 to 7 and data not shown). Since these muta-
tions fall within the catalytic core region, consisting of a His-
Asp-Cys triad (Fig. 1A), the possibility of potential structural
and/or enzymatic activity alterations caused by the mutations
cannot be ruled out.
Identification of a CRM1-dependent NES in SENP2. We
further examined whether SENP2 contains an NES. Proteins
undertaking nuclear export usually have a consensus sequence
comprising several hydrophobic amino acid residues (Leu, Ile,
Phe, etc.) separated by defined spaces (Fig. 3A) (4). Visual
examination of the SENP2 sequence found three potential
NES sequences that fit the consensus (Fig. 3B). To determine
whether any of these sequences comprise a functional NES, we
employed a previously described technique (25) by attaching
short peptides representing each of the three putative NES
domains to the N terminus of YFP and examining the local-
ization of the fusion proteins in transiently transfected cells. In
the absence of a functional NLS and NES, a “naked” YFP is
passively diffused throughout the nucleus and the cytoplasm,
with mild accumulation in the nucleus (Fig. 3C, panel 1). When
each of the NES-like peptides was fused with YFP, the fusion
of residues 143 to 155 with YFP [(143–155)-YFP] did not alter
YFP’s diffused localization pattern, indicating that it is not a
functional NES in the context of YFP (Fig. 3C, panel 5). The
(1–15)-YFP and the (317–332)-YFP fusions, on the other
FIG. 4. Function of NES in SENP2 export. (A) Schematic diagram of human SENP2 and its deletion mutants. Positions of the NLS and NES
and of the N-terminal fusion of GFP are indicated. (B and C) Localization of GFP-SENP2 fusion proteins in transiently transfected U2OS cells.
Plasmid DNA encoding each of the indicated GFP-SENP2 fusion proteins was transfected into U2OS cells, and the GFP signal was examined with
a fluorescence microscope 24 h after transfection into live cells. Corresponding phase-contrast pictures are also shown. (D) The NES-mediated
nuclear export of SENP2 is blocked by LMB. Plasmids expressing various GFP-SENP2 fusion proteins were transfected into U2OS cells.
Twenty-four hours after transfection, the cells were treated with 10 nM LMB for 7 h and microscope pictures were taken with living cells.
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hand, displayed nuclear exclusion, suggesting that they may be
functional NES domains in the context of YFP (Fig. 3C, panels
2 and 6). To further confirm whether these NES sequences are
genuine, leucine-rich, CRM1-dependent NES domains, we in-
troduced mutations into putative essential leucine residues or
treated cells with the CRM1 inhibitor leptomycin B (LMB)
and examined fusion protein localization in live cells. Muta-
tions of the leucine residues or treatment of the cells with LMB
did not affect the nuclear exclusion of (1–15)-YFP (Fig. 3C,
panels 3 and 4) but completely abrogated the nuclear exclusion
of (317–332)-YFP (Fig. 3C, panels 7 and 8), demonstrating
that amino acid residues 317 to 332 comprise an autonomous
CRM1-dependent NES but that the sequence within residues
1 to 15 does not. The cause of nuclear exclusion of the (1–15)-
YFP fusion protein remains unclear. A quantitative summary
of the mutational analysis completed by randomly scoring
more than 200 cells positively transfected with the NES-YFP
fusion is shown in Fig. 3D. (The data shown here represent one
of three independent experiments). Taken together, these re-
sults demonstrate that SENP2 contains an autonomous NES,
at least in the context of a YFP fusion, in the nonconserved
central domain of the protein (residues 317 to 332) that func-
tions through the CRM1-dependent nuclear export pathway.
SENP2 is a shuttling protein. Having found both an NLS
and an NES in SENP2, we hypothesized that SENP2 might be
a shuttling protein undergoing nuclear import and export via
the NLS and the NES. To determine whether SENP2 indeed
shuttles between the nucleus and the cytoplasm, we carried out
two experiments that are commonly used to demonstrate pro-
tein shuttling. First, we determined whether the NES identified
at residues 317 to 332 acts as a true nuclear export signal
sequence in the context of SENP2 protein. To this end, we
generated green fluorescent protein (GFP) fusion constructs
expressing either full-length SENP2 or SENP2 deletions lack-
ing the NLS but retaining the NES (Fig. 4A). When transiently
expressed in U2OS cells, the full-length GFP-SENP2 fusion
protein showed typical nuclear punctate localization, indicat-
ing that attachment of a GFP moiety has not affected SENP2’s
normal subcellular localization (Fig. 4B, panel 1). On the other
hand, GFP fused with each of the three SENP2 deletion mu-
tants lacking the NLS displayed nuclear exclusion (Fig. 4B,
panels 2 to 4). The nuclear exclusion pattern indicated that the
fusion protein was unable to enter the nucleus due to a lack of
NLS; alternatively, the relative strength of the NES activity in
the absence of the NLS may have enabled more-efficient ex-
port of the fusion protein. To distinguish between the two
possibilities, we introduced mutations to the essential leucine
residues in the SENP2 NES and examined the localization of
the mutant proteins (GFP-SENP2mNES). As shown in Fig. 4C,
while the localization of full-length SENP2-GFP was not af-
fected by the NES mutation as expected (panel 1), localization
of the three NLS deletion mutants was altered by the NES
mutation and all exhibited substantial nuclear accumulation
(Fig. 4C, panels 2 to 4). This indicates that the NES indeed
functions in the context of the SENP2 protein, at least when
the NLS is deleted. To demonstrate that the function of NES
is CRM1 dependent, we treated the transfected cells with LMB
to specifically inhibit the CRM1-dependent nuclear export ac-
tivity of the NES (8). LMB treatment effectively reversed the
nuclear exclusion pattern of the fusion protein (Fig. 4D), dem-
onstrating that the function of the NES, and thus the nuclear
export of SENP2, is CRM1 dependent. We noticed that
the SENP2 fragments with C-terminal deletions were less ca-
pable of forming speckles, similar to what occurs with the
SENP2mcNLS mutant, which has a mutated putative C-terminal
NLS (Fig. 2A, row 7). The mechanism by which the mutations
disrupt SENP2 speckles remains to be determined.
Next, we carried out an interspecies heterokaryon assay to
directly show the nucleocytoplasmic shuttling of SENP2. Hu-
man U2OS cells were transiently transfected with either wild-
type GFP-SENP2 or an NES mutant GFP-SENP2mNES fusion
construct. One day after transfection, the cells were fused with
MEF cells by PEG in the presence of cycloheximide (50 g/ml)
to block de novo protein synthesis. Accumulation of the GFP-
tagged SENP2 protein in the mouse nucleus of the hetero-
karyon indicates that the protein has been exported out of the
human nucleus into the shared cytoplasm and imported into
the mouse nucleus. Using this technique, we found that a signif-
icant amount of GFP-SENP2 relocalized to the mouse nucleus
after 5 h of incubation in the majority of the heterokaryons ran-
domly examined (Fig. 5A and C). GFP-SENP2mNES, where the
NES is mutated, remained in the human nucleus in the hetero-
karyons (Fig. 5B and C). Thus, together with the results from Fig.
1 to 5, we conclude that SENP2 shuttles between the nucleus and
the cytoplasm through an NLS identified at residues 29 to 49 and
an NES at residues 317 to 332.
SUMO-modified PML, but not RanGAP1, can be efficiently
deconjugated by SENP2. SENP2 desumoylates a large number
of cellular proteins modified by either SUMO-1 or SUMO-3
(our unpublished results), indicating the involvement of
SENP2 in various aspects of cellular function. In a study of
substrate specificity of SENP2, we examined the activity of
SENP2 in desumoylating PML and RanGAP1, two of the most
abundantly sumoylated proteins in cells. An added advantage
of using PML and RanGAP1 as SENP2 substrates in the study
is that the endogenous sumoylation activity is sufficient to
modify both proteins when they are exogenously expressed.
We carried out an in vivo sumoylation assay with H1299 cells
transiently transfected with His-tagged PML or RanGAP1
along with SUMO-1, SUMO-3, and SENP2 in various combi-
nations. Cells were lysed with hot SDS lysis buffer to prevent
SUMO-conjugated proteins from desumoylation during sam-
ple preparation, and the SUMO-modified PML and RanGAP1
were detected by a Western blotting assay using an anti-His
antibody. Using this assay, His-PML was efficiently modified by
endogenous sumoylation activity and detected by an anti-His
antibody. SUMO-modified PML was detected as several dis-
crete bands presumably resulting from the monosumoylation
of three SUMO sites on PML (15) (Fig. 6A, lanes 2 and 4).
When SENP2 was coexpressed, the SUMO-1- and SUMO-3-
modified PML was completely deconjugated (Fig. 6B, lanes 2
and 4), indicating that PML is either a direct substrate of
SENP2 in vivo or indirectly affected by SENP2 activity. In
contrast to PML and consistent with a previous report (12),
the sumoylated RanGAP1 was mostly resistant to SENP2 de-
sumoylation activity (Fig. 6C). Thus, in cell culture, the
SUMO-modified PML, but not the SUMO-modified Ran-
GAP1, is efficiently deconjugated by SENP2. It was postulated
that the distinct subcellular localization of SENP enzymes
plays an important role in their function, particularly in sub-
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strate selection (19, 23). It is possible that SENP2, a nuclear
protein, efficiently deconjugates only nucleus-localized PML
and not cytoplasm-localized RanGAP1, as shown with the dis-
tinct subcellular localizations in cells (Fig. 6D). However, our
experiments (see below) suggest that the resistance of Ran-
GAP1 to desumoylation by SENP2 was not just due to its
discrete localization from SENP2.
Disruption of the NLS, but not the NES, impairs the pro-
tease function of SENP2. It is possible that the discrete cellular
localizations of SENP2 (in the nucleus) and RanGAP1 (in the
cytoplasm) contributed to RanGAP1’s resistance to SENP2
desumoylation. With the identification of the NLS and con-
struction of a cytoplasm-localized SENP2mNLS mutant, we
wanted to determine whether the nuclear localization of
SENP2 plays a role in its protease function. To this end, we
constructed a Myc-tagged, wild-type SENP2 (Myc-SENP2),
an NLS mutant (Myc-SENP2mNLS), an NES mutant (Myc-
SENP2mNES), and an NLS/NES double mutant (Myc-
SENP2mNLS/mNES) and tested the function of the SENP2 con-
structs by an in vivo sumoylation assay. We first determined
whether nuclear import and/or export of SENP2 affects its
desumoylation activity toward total SUMO-modified cellular
proteins. The various SENP2 proteins, along with HA-
SUMO-3, were expressed in H1299 cells. Total sumoylated
cellular proteins were detected with an anti-HA antibody in a
Western blotting assay. The SENP2mNES mutant appeared to
have desumoylation activity similar to that of wild-type SENP2
(Fig. 7A, compare lane 4 with lane 2). The SENP2mNLS mu-
tant, on the other hand, exhibited substantially reduced activity
compared to those of wild-type and NES mutant SENP2 (Fig.
7A, lane 3), indicating that the nuclear import of SENP2 is
important for its protease function. Because the SENP2mNLS
mutant localizes to the cytoplasm (Fig. 2), this result also
indicated that many of the SENP2 substrates might reside in
the nucleus. To substantiate this possibility, a SENP2 mu-
tant containing mutations in both the NLS and NES
(SENP2mNLS/mNES) was generated, resulting in a mutant with
a more-diffuse subcellular localization than that of either
SENP2mNLS or SENP2mNES alone (data not shown). The de-
sumoylation activity exhibited by SENP2mNLS/mNES was some-
what in between that of the SENP2mNLS and the SENP2mNES
mutants (Fig. 7A, lane 5). The impairment of the desumoyla-
tion function by the NLS mutation, however, appeared to be
limited. We believe that this is most likely due to a combina-
tion of incomplete disruption of the NLS by the point muta-
tions and a leakage of the mutant protein caused by overex-
pression. A small amount of the SENP2mNLS mutant protein
entering the nucleus could have sufficient protease activity to
deconjugate a large amount of SUMO-modified proteins.
To further examine functional alterations of the SENP2
FIG. 5. Interspecies heterokaryon assay shows that SENP2 is a
shuttling protein. U2OS cells were transfected with plasmids express-
ing wild-type GFP-SENP2 (A) or the NES mutant GFP-SENP2mNES
(B) fusion proteins. Twenty-four hours after transfection, the cells
were washed and fused to wild-type MEF cells, and de novo protein
synthesis was blocked by cycloheximide. Five hours after fusion, the
cells were fixed and stained with an antibody to human Ku antigen,
followed by staining with a rhodamine-conjugated secondary antibody.
Representative heterokaryons were photographed. Nuclei of human
(h) and mouse (m) origin in each heterokaryon are indicated. (C)
Quantification of cells exported from the nucleus. Twenty-five ran-
domly chosen heterokaryons from four independent heterokaryon as-
says described for panels A and B were examined, and the results were
plotted.
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NLS and NES mutants, we compared their activities in de-
sumoylating PML and RanGAP1, a nuclear protein and a
cytoplasmic protein, respectively. His-PML and His-RanGAP1
were each coexpressed with SENP2 or SENP2 mutants in
H1299 cells, and SUMO-modified His-PML and His-Ran-
GAP1 were detected by an anti-His antibody. A catalytically
inactive SENP2Cat mutant was used as a negative control. As
shown in Fig. 7B and C, ectopically expressed His-PML and
His-RanGAP1 were efficiently modified by endogenous sumoy-
lation activity in the absence of SENP2 (lane 1 in Fig. 7B and C).
With coexpression of increasing amounts of SENP2, the
SUMO-modified PML was reduced in a dose-dependent man-
FIG. 6. SUMO-modified PML, but not RanGAP1, is efficiently deconjugated by SENP2. (A to C) H1299 cells were transfected with the
indicated plasmids, and cells were lysed 2 days after transfection with hot SDS (2%) lysis buffer. The cell lysate was resolved by SDS-PAGE and
blotted with the indicated antibodies (). GFP was used as a loading control for transfection efficiency. K, in thousands. (A and B) Unmodified
and sumoylated His-tagged PML were detected with anti-His antibody. Unconjugated SUMO (free SUMO) was detected with anti-HA antibody.
(C) Unmodified RanGAP1 and sumoylated His-tagged RanGAP1 were detected with an anti-His antibody. Unconjugated SUMO (free SUMO)
was detected with anti-HA antibody. (D) Localization of PML and RanGAP1. U2OS cells were transfected with His-PML or His-RanGAP1.
Twenty-four hours after transfection, cells were fixed and immunostained with an anti-His antibody, followed by staining with Cy2-conjugated or
rhodamine-conjugated secondary antibody. Immunofluorescent, phase-contrast, and DAPI-stained images are shown.
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ner, indicating that PML is a cellular substrate of SENP2 (Fig.
7B). Importantly, among the three SENP2 proteins (SENP2,
SENP2mNLS, and SENP2mNES), SENP2mNLS exhibited the
lowest desumoylation activity toward PML, even though the
protein expressed at comparable or higher levels (Fig. 7B,
compare lanes 11 to 12 with lanes 5 to 6 and 15 to 16). On the
other hand, SENP2mNES appeared to be the most active in
desumoylating PML. Given that PML is a nuclear protein (Fig.
6D), these results indicate that colocalization with PML in the
nucleus is important for SENP2 to desumoylate PML. In con-
FIG. 7. Disruption of the NLS, but not NES, impairs the protease function of SENP2. (A) H1299 cells were cotransfected with plasmids
encoding HA-SUMO-3 and various Myc-SENP2 enzymes as indicated. The SENP2 constructs were transfected with wild-type SENP2 [WT]–
SENPmNLS–SENPmNES–SENPmNLS/mNES at a ratio of 1:1.5:0.7:1.1 to obtain equal levels of SENP2 protein expression. Cells were lysed 2 days after
transfection with a 2% hot SDS lysis buffer. Cell lysates were separated by SDS-PAGE, and the proteins were detected by immunoblotting with
the indicated antibodies (). GFP was used as a loading control for transfection efficiency. High-molecular-weight protein species detected with
an anti-HA antibody indicate sumoylated proteins. Unconjugated SUMO-3 (free SUMO-3) is shown. (B) Desumoylation of PML by SENP2.
H1299 cells were cotransfected with plasmids encoding His-PML and various Myc-SENP2 enzymes as indicated. The SENP2 constructs were
transfected with wild-type Myc-SENP2–SENPmNLS–SENPmNES at a ratio of 1:1.2:0.7 to obtain similar levels of SENP2 protein expression. Cells
were lysed 2 days after transfection with a 2% hot SDS lysis buffer. Cell lysates were subjected to SDS-PAGE and immunoblotted (IB) with the
indicated antibodies. Unmodified and sumoylated His-PML was detected with anti-His antibody. Cat, a catalytically inactive SENP2 mutant.
(C) Desumoylation of RanGAP1 by SENP2. H1299 cells were cotransfected with plasmids encoding His-RanGAP1 and the wild-type or mutant
Myc-SENP2. The SENP2 constructs were transfected with wild-type Myc-SENP2–SENPmNLS–SENPmNES–SENP2Cat [Cat]) at a ratio of 1:1.5:0.7:
1.5 to obtain equal levels of SENP2 protein expression. Cells were lysed 2 days after transfection with a 2% hot SDS lysis buffer, and the cell lysates
were assayed as described for panel B.
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FIG. 8. SENP2 is degraded through polyubiquitination-mediated proteolysis. (A) Half-life assay of SENP2. H1299 cells were transfected with
plasmid DNA encoding wild-type Myc-tagged SENP2 (WT) or SENP2 mutants. Twenty-four hours after transfection, cells were pulse-labeled with
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trast to PML, SUMO-modified RanGAP1 was resistant to
desumoylation by any of the three catalytically active SENP2
enzymes. However, we did notice that the SENP2mNLS mutant,
which is the least effective in desumoylating PML, appeared to
be more effective in desumoylating RanGAP1 than were wild-
type SENP2 and SENP2mNES (compare lane 3 with lanes 2 and
4 in Fig. 7C). Together, these results suggest that the colocal-
ization of SENP2 with its substrates in the same subcellular
compartment facilitates SUMO deconjugation.
Regulation of SENP2 by polyubiquitination-mediated deg-
radation. Although we have demonstrated SENP2 shuttling
between the nucleus and cytoplasm, the predominance of wild-
type SENP2 nuclear localization, combined with the results of
our mutational analysis, suggests that the protease activity of
SENP2 occurs in the nucleus. Based on the characterization
of other shuttling proteins, such as cyclin B, E2F1, p53, and
MDM2, whose shuttling activities are linked to protein degra-
dation, we sought to determine whether SENP2 protein sta-
bility could be affected by its shuttling. To this end, we exam-
ined SENP2 protein stability by a half-life assay. SENP2 and
SENP2 mutants were transiently expressed in H1299 cells,
pulse-labeled with [35S]methionine for 2 h, and chased every
6 h for up to 24 h. The assay showed that the SENP2mNLS
mutant has a much shorter half-life than wild-type SENP2 and
the SENP2mNES mutant (Fig. 8A). Reducing the time interval
in the half-life assay revealed that the SENP2mNLS mutant has
a half-life of approximately 3 h (Fig. 8B and C). The shorter
half-life of the cytoplasm-localized SENP2mNLS mutant
than those of wild-type SENP2 and the nucleus-localized
SENP2mNES mutant suggests that the degradation of SENP2
occurs in the cytoplasm. It also argues that the decreased
stability of the SENP2mNLS mutant could contribute to the
observed overall lower activity of this mutant in deconjugating
total cellular SUMO-modified proteins (Fig. 7A). The shorter
half-life of the SENP2mNLS mutant was also consistent with the
observation that a larger amount of the SENP2mNLS mutant
DNA than of SENP2 or SENP2mNES DNA is required to achieve
equal levels of protein expression following transient transfection.
Ectopically expressed proteins tend to have a longer half-life than
those that are endogenously expressed; therefore, under physio-
logical conditions, SENP2’s half-life could be shorter than those
that we observed in this assay. The lack of antibodies able to
immunoprecipitate endogenous SENP2 limited our ability to de-
termine its half-life under physiological conditions.
The short half-life of SENP2 suggests that it might undergo
ubiquitin-mediated proteolysis. To determine whether SENP2
is ubiquitinated and degraded through proteolysis, we carried
out an in vivo ubiquitination assay by transfecting H1299
cells with plasmid DNA expressing HA-Ub and Myc-tagged
SENP2. Two identical sets of samples were prepared: one
untreated control and one treated with the 26S proteasome
inhibitor MG132 to allow ubiquitinated proteins to accumu-
late. After cells were lysed in hot SDS lysis solution (to protect
ubiquitinated protein species from deubiquitination), Myc-
tagged SENP2 was pulled down with an anti-Myc antibody and
separated on an SDS-PAGE gel, and HA-Ub-conjugated
SENP2 was detected with an anti-HA antibody. As shown in
Fig. 8D, polyubiquitinated SENP2 was barely seen without
MG132 treatment (lanes 3 to 5). In samples treated with
MG132, however, high-molecular-weight polyubiquitinated
SENP2 was readily detected, demonstrating that SENP2 can
be efficiently polyubiquitinated in vivo (lanes 8 to 10). Immu-
nofluorescent staining indicated that MG132 treatment did not
affect the localization of SENP2 or the SENP2 mutants (Fig.
8E). Notably, we found that among the three SENP2 proteins,
SENP2mNLS was ubiquitinated to the greatest extent, suggest-
ing that the polyubiquitination of SENP2 occurs more effi-
ciently in the cytoplasm. Alternatively, this effect could be due
to a higher deubiquitination activity in the nucleus, which
would be consistent with an observed lower level of polyubiq-
uitination in the SENP2mNES mutant than in wild-type SENP2
(Fig. 8D, compare lanes 8 and 10), yet both proteins have
similar half-lives, and our results indicate that ubiquitination
and proteasomal degradation might not be entirely linked in
this case. The higher level of ubiquitination of SENP2mNLS
correlates with its shorter half-life, indicating that SENP2 is de-
graded through an ubiquitin-mediated proteolysis pathway. Given
that the ubiquitination assay was performed without coexpressing
an E3 ubiquitin ligase, the observed polyubiquitination of SENP2
must be achieved by an endogenous ubiquitin ligase. Thus, it
appears that the in vivo ubiquitination activity of SENP2 is rather
high. Taken together, our data demonstrate that SENP2 can be
polyubiquitinated in vivo and degraded by 26S proteasome-me-
diated proteolysis. These data also indicate that the polyubiquiti-
nation of SENP2 takes place preferentially in the cytoplasm.
DISCUSSION
In analyzing the mechanisms controlling SENP2 function,
we examined the nucleocytoplasmic shuttling of SENP2. Sev-
[35S]methionine for 2 h and chased for the indicated lengths of time. Cell lysates were immunoprecipitated with anti-Myc antibody. The resulting
SENP2 immunoprecipitates were separated by SDS-PAGE and visualized by autoradiography. (B) Half-life assay of SENP2 as described for panel
A except with shorter time intervals, as indicated. The amount of labeled SENP2 protein at each time point was quantified on a PhosphorImager
and normalized relative to the amount of radiolabeled SENP2 present in cells following the 0 h chase. Average results of four independent
experiments were plotted in panel C. (D) In vivo ubiquitination assay of SENP2. H1299 cells were transfected with the indicated plasmid DNA.
The GFP plasmid was also cotransfected as a control for transfection efficiency. The SENP2 constructs were transfected with wild-type Myc-
SENP2–SENPmNLS–SENPmNES at a ratio of 1:1.5:0.7 to obtain equal levels of SENP2 protein expression. Two days after transfection, cells were
treated with 20 M MG132 for 6 h. Cells were lysed in 1% SDS lysis buffer and diluted 10 times with 0.1% NP-40–PBS. Diluted lysates were
immunoprecipitated (IP) with anti-Myc antibody. The resulting SENP2 immunoprecipitates were separated by SDS-PAGE and immunoblotted
(IB) with the indicated antibodies (). K, in thousands; [Ub]n-SENP2, polyubiquitinated SENP2; expo, exposure. (E) Localization of wild-type
SENP2 or its mutants after the treatment with MG132. U2OS cells were transfected with plasmid DNA encoding Myc-tagged SENP2. Twenty-four
hours after transfection, cells were treated with 20 M MG132 for 10 h, fixed, and immunostained with anti-Myc antibody, followed by staining
with Cy2-conjugated secondary antibody.
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eral lines of evidence have emerged from this study: (i) SENP2
has a bipartite NLS and a CRM1-dependent NES, both of
which are located in nonconserved domains in SENP2 and are
not found in other members of the SENP family; (ii) SENP2
shuttles between the nucleus and the cytoplasm via its NLS and
NES; (iii) colocalization of SENP2 with substrates in the same
subcellular compartment facilitates SUMO deconjugation; and
(iv) SENP2 is polyubiquitinated in vivo and degraded by the
26S proteasome-dependent pathway.
An NES-mediated nuclear export of SENP2 may serve two
purposes. The first possible role may be to add another layer of
regulation for SENP2 activity and substrate selectivity. In the-
ory, SENP2 could have substrates in both the nucleus and the
cytoplasm. When and how much of these substrates must be
desumoylated could be influenced by cellular functions, such as
cell cycle progression. By controlling the function of the nu-
cleocytoplasmic shuttling of SENP2, cells may be able to se-
lectively desumoylate specific substrates in the nucleus and/or
in the cytoplasm, thereby achieving a greater flexibility in reg-
ulating SENP2 activity. The second purpose concerns the role
of nucleocytoplasmic shuttling in controlling SENP2 protein
turnover. Our data show that SENP2 is efficiently polyubiquitin-
ated in vivo and undergoes polyubiquitin-mediated proteaso-
mal degradation and that the polyubiquitination of SENP2
appears to occur preferentially in the cytoplasm. Based on our
data, we envision a model for SENP2 nucleocytoplasmic shut-
tling whereby SENP2 enters the nucleus via NLS-mediated
nuclear import and functions as a nucleus-specific SUMO pro-
tease. When SENP2’s activity is no longer required or needs to
be reduced, the protein is exported out of the nucleus via
NES-dependent nuclear export. As a result, polyubiquitination
occurs in the cytoplasm and SENP2 is degraded through the
26S proteolysis pathway. This mechanism could effectively sep-
arate the locations of SENP2’s function (in the nucleus) and
destruction (in the cytoplasm), so that premature degradation
of SENP2 can be prevented when its activity is needed in the
nucleus.
We have noticed that even though the impairment of nu-
clear localization of SENP2 by NLS mutation is considerably
thorough, the impairment of the desumoylation function of the
mutant appears to be limited. Two possibilities may contribute
to this discrepancy. First, it is possible that the SUMO-modi-
fied protein substrates travel between the nucleus and the
cytoplasm, allowing a cytoplasm-restricted SENP2mNLS to de-
conjugate nuclear substrates in the cytoplasm without entering
the nucleus. The second alternative may involve only partial
inhibition of SENP2mNLS nuclear localization due to either
incomplete inactivation of the NLS or protein expression levels
far in excess of physiological levels. In this case, even a minor
fraction of ectopically expressed SENP2 entering the nucleus
could have sufficient protease activity to process a large quan-
tity of substrate. An earlier report has shown that elimination
of the first 70 amino acids of SENP2, the region containing the
NLS, affected SENP2’s association with the nuclear pore and
increased the capacity of SENP2 to deconjugate SUMO-1-
conjugated proteins in cells. Hang and Dasso suggested that
the association of SENP2 to the nuclear pore may have a
negative impact on the function of SENP2 (12). Our results,
using conjugated point mutant SENP2 and SUMO-3 proteins,
indicate that the cytoplasmically confined SENP2 mutant was
less active in desumoylating SUMO-3-conjugated cellular pro-
teins (Fig. 7A). Whether the discrepancy reflects functional
differences between an N-terminally truncated SENP2 and a
full-length SENP2 or differential activities of the SENP2 mu-
tants toward SUMO-1- and SUMO-3-conjugated cellular pro-
teins remains to be determined.
To date, all the SENP species identified in mammalian cells
have divergent N-terminal domains, believed to be involved in
determining the substrate specificity of each SENP protease
(14, 23). Individual SENP species have been found in different
subcellular compartments. For example, SENP1 localizes to
the nuclear foci and the nuclear rim (3), SENP2 localizes to the
nuclear side of the nuclear pore complex (12, 24), SENP3
localizes to the nucleolus (20), and SENP6 is found primarily
in the cytoplasm (16). It is conceivable that the diverse subcel-
lular localizations of the proteases play important roles in
determining their substrate specificities. Nevertheless, how a
specific subcellular localization is linked to the function of each
SENP protease remains poorly understood.
How sumoylation, and particularly desumoylation, might af-
fect the biological processes of cells is unclear. Sumoylation
has been implicated in many cellular functions, including reg-
ulation of transcription, formation of PML nuclear bodies,
chromosome organization, DNA repair, and nuclear transport
(14, 22). A common problem in examining the functional con-
sequences of sumoylation/desumoylation is that, with rare ex-
ceptions, the proportion of most SUMO-modified proteins,
compared with that of those lacking SUMO modifications, is
always extremely low. Therefore, it is not clear in most cases if
any specific biological function can be attributed to SUMO
modifications or whether the fraction of sumoylated protein
bears any physiological significance. There may be multiple
potential explanations concerning the nature of low sumoy-
lated-protein levels, but at the very least we will consider two
of them. First, much like polyubiquitinated proteins, SUMO-
modified proteins may escape detection by becoming unstable
and short-lived during sample preparations. It is of interest to
note that sumoylation and ubiquitination may be intimately
linked (9), considering the fact that many sumoylated proteins
are also ubiquitinated and degraded by proteolysis. Whether
sumoylation competes with ubiquitination on the same lysine
residues or is a prerequisite for ubiquitination and subsequent
degradation is unknown. A second potential factor for the low
level of sumoylation could be high desumoylation activity in
cells. We postulate that protein sumoylation might occur con-
stitutively in cells and that the control steps for SUMO mod-
ification might be at the steps of desumoylation, but not
sumoylation. If so, SUMO proteases could represent a group
of new targets for therapeutic intervention in certain human
diseases, including cancer, for which studies have suggested
that altered sumoylation may contribute to both the onset and
progression of the disease (1).
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